HOSPITAL UNIVERSITARIO RUBER
Departamento
Cancer Research UK
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Cancer Research UK (4)
2020
2019
-
POSEIDON trial phase 1B results: Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients
Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6598-6605
-
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12